Dexcom (NSDQ:DXCM) shares are up more than 13% today — a day after Q2 results that topped the consensus forecast. The San Diego-based continuous glucose monitor developer also announced continued clinical and regulatory progress with its next-gen G7, though the timing of a U.S. G7 release is still an open question. Dexcom posted profits of […]
Patient Monitoring
Abbott launches latest insertable cardiac monitor
Abbott (NYSE:ABT) announced that it launched the Jot Dx — its latest insertable cardiac monitor (ICM) — in the U.S. Jot Dx offers clinicians and hospitals control of the management of the flow of information through a feature that allows the viewing of abnormal heart rhythm data. It can simplify which irregular heart rhythms are […]
ConMed beats The Street in Q2, raises full-year guidance
ConMed (NSDQ:CNMD) reported second-quarter results that beat the consensus forecast on Wall Street. The Largo, Fla.–based surgical and patient monitoring products company posted profits of $13.3 million, or 41¢ per share, on sales of $255.2 million for the three months ended June 30, 2021. The results out yesterday evening showed a massively improving bottom line […]
Hillrom stock shoots up on news of potential acquisition by Baxter
Hillrom (NYSE: HRC) stock rocketed today after a Wall Street Journal report that Baxter (NYSE: BAX) is in the early stages of talks to acquire the company. WSJ cited people familiar with the matter, who added that there was no guarantee the two companies will reach an agreement. HRC shares are up 8.7% to $134.49 […]
AliveCor, Acutus partner on remote monitoring pilot study
AliveCor and Acutus Medical (NSDQ:AFIB) today announced a collaboration to study the integration of data collection tools in cardiology. The companies plan to launch a post-market U.S. pilot study in the third quarter of 2021 to gain insights on how physicians can use AliveCor’s KardiaMobile electrocardiogram (ECG) device to facilitate pre-ablation and/or post-ablation remote monitoring […]
LifeSignals remote patient monitor wins FDA clearance
LifeSignals today announced that it has received FDA 510(k) clearance for its LX1550 multi-parameter remote monitoring platform. Fremont, Calif.–based LifeSignals designed the LX1550 to continuously collect patient physiological data from home and in healthcare settings. Get the full story on our sister site, Medical Design & Outsourcing.
The 18 most innovative medical devices of 2021
The Galien Foundation today announced the nominees for most innovative medical devices for its 15th annual Prix Galien USA Awards. The foundation nominates devices, biotechnology and pharmaceutical products for its annual Prix Galien awards to highlight products designed to improve the human condition. “The Awards Committee is excited to introduce the nominees for the 2021 […]
Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’
As we enter what may be the “new normal,” Dexcom’s CEO bets the company can pave the way in continuous glucose monitoring. Dexcom (NSDQ:DXCM), like any company seeking to innovate, remains in a state of perpetual forward motion. That’s the way chair, president & CEO Kevin Sayer views it, anyway. As the company looks toward the […]
FDA clears Dexcom Partner Web APIs
Dexcom (NSDQ:DXCM) announced today that it received FDA clearance for its Dexcom Partner Web application programming interfaces (APIs). The San Diego–based company’s Dexcom Partner Web APIs enable invited third-party developers to integrate real-time continuous glucose monitoring (CGM) data into their digital health apps and devices. Get the full story at our sister site, Drug Delivery Business […]
Pear Therapeutics touts 9-month data for reSET-O
Pear Therapeutics today touted results from an extended retrospective analysis of real-world data for its reSET-O prescription digital therapeutic. Boston-based Pear Therapeutics developed its reSET-O prescription digital therapeutic (PDT) for treating opioid use disorder (OUD). Get the full story at our sister site, Drug Delivery Business News.
Glytec appoints chief medical officer
Cloud-based insulin management software developer Glytec announced today that it appointed Dr. Jordan Messler as chief medical officer. Messler’s responsibilities as the company’s CMO include spearheading continuous improvement initiatives for Glytec’s clinical strategy and product development. Get the full story at our sister site, Drug Delivery Business News.